A systematic review of the effect of genes mediating neurodevelopment and neurotransmission on brain morphology: Focus on schizophrenia

Neurology Psychiatry and Brain Research

Volumn 21, Issue 1, 2015, Pages 1-26

  John, John P ^a   Thirunavukkarasu, Priyadarshini ^a   Halahalli, Harsha N ^a,b   Purushottam, Meera ^a   Jain, Sanjeev ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b NITTE UNIVERSITY   (India)

Author keywords

Brain volume; Gene interactions; GWAS; In silico analysis; Morphometry; Neurodevelopment; Neurotransmission; Risk genes; Schizophrenia; SNP

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMINO ACID OXIDASE ACTIVATOR; APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE; DYSBINDIN; GLUTAMATE DECARBOXYLASE 67; GLUTAMATE RECEPTOR 1; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1; INTERLEUKIN 6; MEMBRANE PROTEIN; MYELIN ASSOCIATED GLYCOPROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NEUROGENIC LOCUS NOTCH HOMOLOG PROTEIN 4; NEUROGENIN 1; NEUROGRANIN; NEUROTROPHIN 3; NOTCH4 RECEPTOR; PERICENTRIOLAR MATERIAL 1 PROTEIN; PLEXIN B3; PRION PROTEIN; REELIN; TRANSCRIPTION FACTOR FOXP2; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VACCINIA RELATED KINASE 2; ZINC FINGER BINDING PROTEIN 804A;

ARTICLE; BRAIN; BRAIN SIZE; CHROMOSOME 22Q; DNA POLYMORPHISM; DOPAMINERGIC TRANSMISSION; ENDOPHENOTYPE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; SYNAPTIC TRANSMISSION; SYSTEMATIC REVIEW;

EID: 84931268650     PISSN: 09419500     EISSN: 22128581     Source Type: Journal    
DOI: 10.1016/j.npbr.2014.11.003     Document Type: Review

References (285)

1. Perlini C, Bellani M, Brambilla P. Structural imaging techniques in schizophrenia. Acta Psychiatr Scand 2012;126:235-42.
2. Shenton ME, Whitford TJ, Kubicki M. Structural neuroimaging in schizophrenia: from methods to insights to treatments. Dialogues Clin Neurosci 2010;12:317-32.
3. Harvey I, Ron MA, Du Boulay G, Wicks D, Lewis SW, Murray RM. Reduction of cortical volume in schizophrenia on magnetic resonance imaging. Psychol Med 1993;23:591-604.
4. Lim KO, Tew W, Kushner M, Chow K, Matsumoto B, DeLisi LE. Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am J Psychiatry 1996;153:1548-53.
5. Gaser C, Nenadic I, Buchsbaum BR, Hazlett EA, Buchsbaum MS. Ventricular enlargement in schizophrenia related to volume reduction of the thalamus, striatum, and superior temporal cortex. Am J Psychiatry 2004;161:154-6.
6. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005;162:2233-45.
7. Ioannidis JP. Excess significance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry 2011;68:773-80.
8. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 2000;47:210-20.
9. van Haren NE, Bakker SC, Kahn RS. Genes and structural brain imaging in schizophrenia. Curr Opin Psychiatry 2008;21:161-7.
10. Kempton MJ, Ruberto G, Vassos E, Tatarelli R, Girardi P, Collier D, et al. Effects of the CACNA1C risk allele for bipolar disorder on cerebral gray matter volume in healthy individuals. Am J Psychiatry 2009;166:1413-4.
11. Sullivan PF. Puzzling over schizophrenia: schizophrenia as a pathway disease. Nat Med 2012;18:210-1.
12. Schizophrenia Psychiatric Genome-Wide Association Study Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011;43:969-76.
13. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013;45:1150-9.
14. Plomin R, Owen MJ, McGuffin P. The genetic basis of complex human behaviors. Science 1994;264:1733-9.
15. Bassett AS, Scherer SW, Brzustowicz LM. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am J Psychiatry 2010;167:899-914.
16. Hosak L. New findings in the genetics of schizophrenia. World J Psychiatry 2013;3:57-61.
17. Corvin A. Schizophrenia at a genetics crossroads: where to now? Schizophr Bull 2013;39:490-5.
18. Prasad KM, Chowdari KV, Nimgaonkar VL, Talkowski ME, Lewis DA, Keshavan MS. Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients. Mol Psychiatry 2005;10:213-9.
19. Szeszko PR, Hodgkinson CA, Robinson DG, Derosse P, Bilder RM, Lencz T, et al. DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol 2008;79:103-10.
20. Seidman LJ, Pantelis C, Keshavan MS, Faraone SV, Goldstein JM, Horton NJ, et al. A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull 2003;29:803-30.
21. Stefanis N, Frangou S, Yakeley J, Sharma T, O'Connell P, Morgan K, et al. Hippocampal volume reduction in schizophrenia: effects of genetic risk and pregnancy and birth complications. Biol Psychiatry 1999;46:697-702.
22. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry 2004;9:14-27.
23. Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J Psychiatr Res 1999;33:543-8.
24. Maynard TM, Sikich L, Lieberman JA, LaMantia AS. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophr Bull 2001;27:457-76.
25. Kamiya A, Kubo K, Tomoda T, Takaki M, Youn R, Ozeki Y, et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol 2005;7:1167-78.
26. Taya S, Shinoda T, Tsuboi D, Asaki J, Nagai K, Hikita T, et al. DISC1 regulates the transport of the NUDEL/LIS1/14-3-3epsilon complex through kinesin-1. J Neurosci 2007;27:15-26.
27. Cheung YF, Kan Z, Garrett-Engele P, Gall I, Murdoch H, Baillie GS, et al. PDE4B5, a novel, super-short, brain-specific camp phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of camp phosphodiesterase-4D6 (PDE4D6). J Pharmacol Exp Ther 2007;322:600-9.
28. Wilson SW, Houart C. Early steps in the development of the forebrain. Dev Cell 2004;6:167-81.
29. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ. Schizophrenia and affective disorders - cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001;69:428-33.
30. Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, et al. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 2004;75:862-72.
31. Qu M, Tang F, Yue W, Ruan Y, Lu T, Liu Z, et al. Positive association of the disrupted-in-schizophrenia-1 gene (DISC1) with schizophrenia in the Chinese Han population. Am J Med Genet B Neuropsychiatr Genet 2007;144B:266-70.
32. Brauns S, Gollub RL, Roffman JL, Yendiki A, Ho BC, Wassink TH, et al. DISC1 is associated with cortical thickness and neural efficiency. Neuroimage 2011;57:1591-600.
33. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci U S A 2005;102:8627-32.
34. Di Giorgio A, Blasi G, Sambataro F, Rampino A, Papazacharias A, Gambi F, et al. Association of the SerCys DISC1 polymorphism with human hippocampal formation gray matter and function during memory encoding. Eur J Neurosci 2008;28:2129-36.
35. Fode C, Ma Q, Casarosa S, Ang SL, Anderson DJ, Guillemot F. A role for neural determination genes in specifying the dorsoventral identity of telencephalic neurons. Genes Dev 2000;14:67-80.
36. Bertrand N, Castro DS, Guillemot F. Proneural genes and the specification of neural cell types. Nat Rev Neurosci 2002;3:517-30.
37. Schuurmans C, Armant O, Nieto M, Stenman JM, Britz O, Klenin N, et al. Sequential phases of cortical specification involve neurogenin-dependent and -independent pathways. EMBO J 2004;23:2892-902.
38. Fanous AH, Chen X, Wang X, Amdur RL, O'Neill FA, Walsh D, et al. Association between the 5q31.1 gene neurogenin1 and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007;144B:207-14.
39. Ho BC, Epping E, Wang K, Andreasen NC, Librant A, Wassink TH. Basic helix-loop-helix transcription factor NEUROG1 and schizophrenia: effects on illness susceptibility, MRI brain morphometry and cognitive abilities. Schizophr Res 2008;106:192-9.
40. Rice DS, Curran T. Role of the reelin signalling pathway in central nervous system development. Annu Rev Neurosci 2001;24:1005-39.
41. Lachman HM, Petruolo OA, Pedrosa E, Novak T, Nolan K, Stopkova P. Analysis of protocadherin alpha gene deletion variant in bipolar disorder and schizophrenia. Psychiatr Genet 2008;18:110-5.
42. Wedenoja J, Loukola A, Tuulio-Henriksson A, Paunio T, Ekelund J, Silander K, et al. Replication of linkage on chromosome 7q22 and association of the regional reelin gene with working memory in schizophrenia families. Mol Psychiatry 2008;13:673-84.
43. Yang XB, Kang C, Liu H, Yang J. Association study of the reelin (RELN) gene with Chinese Va schizophrenia. Psychiatr Genet 2013;23:138.
44. Gregorio SP, Sallet PC, Do KA, Lin E, Gattaz WF, Dias-Neto E. Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: preliminary evidence. Psychiatry Res 2009;165:1-9.
45. Gorski JA, Zeiler SR, Tamowski S, Jones KR. Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J Neurosci 2003;23:6856-65.
46. Schultz W. Behavioral theories and the neurophysiology of reward. Annu Rev Psychol 2006;57:87-115.
47. Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 2005;10:208-12.
48. Toro R, Chupin M, Garnero L, Leonard G, Perron M, Pike B, et al. Brain volumes and Val66Met polymorphism of the BDNF gene: local or global effects? Brain Struct Funct 2009;213:501-9.
49. Ho BC, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006;63:731-40.
50. Koolschijn PC, van Haren NE, Bakker SC, Hoogendoorn ML, Hulshoff Pol HE, Kahn RS. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus 2010;20:1010-7.
51. Yang X, Liu P, Sun J, Wang G, Zeng F, Yuan K, et al. Impact of brain-derived neurotrophic factor Val66Met polymorphism on cortical thickness and voxel-based morphometry in healthy Chinese young adults. PLoS ONE 2012;7:e37777.
52. Ho BC, Andreasen NC, Dawson JD, Wassink TH. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry 2007;164:1890-9.
53. Wodarz A, Nusse R. Mechanisms of Wnt signalling in development. Annu Rev Cell Dev Biol 1998;14:59-88.
54. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990;9:2431-8.
55. Kozlovsky N, Nadri C, Agam G. Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur Neuropsychopharmacol 2005;15:1-11.
56. Li M, Mo Y, Luo XJ, Xiao X, Shi L, Peng YM, et al. Genetic association and identification of a functional SNP at GSK3beta for schizophrenia susceptibility. Schizophr Res 2011;133:165-71.
57. Benedetti F, Poletti S, Radaelli D, Bernasconi A, Cavallaro R, Falini A, et al. Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity. Genes Brain Behav 2010;9:365-71.
58. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 2007;64:1930-44.
59. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005;30:1223-37.
60. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998;95:13363-83.
61. Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD. Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci U S A 2006;103:3416-21.
62. Tsai MT, Su YC, Chen YH, Chen CH. Lack of evidence to support the association of the human prion gene with schizophrenia. Mol Psychiatry 2001;6:74-8.
63. Weis S, Haybaeck J, Dulay JR, Llenos IC. Expression of cellular prion protein (PrP(c)) in schizophrenia, bipolar disorder, and depression. J Neural Transm 2008;115:761-71.
64. Rujescu D, Meisenzahl EM, Giegling I, Kirner A, Leinsinger G, Hegerl U, et al. Methionine homozygosity at codon 129 in the prion protein is associated with white matter reduction and enlargement of CSF compartments in healthy volunteers and schizophrenic patients. Neuroimage 2002;15:200-6.
65. Kubo A, Tsukita S. Non-membranous granular organelle consisting of PCM-1: subcellular distribution and cell-cycle-dependent assembly/disassembly. J Cell Sci 2003;116:919-28.
66. Kamiya A, Tan PL, Kubo K, Engelhard C, Ishizuka K, Kubo A, et al. Recruitment of PCM1 to the centrosome by the cooperative action of DISC1 and BBS4: a candidate for psychiatric illnesses. Arch Gen Psychiatry 2008;65:996-1006.
67. Gurling HM, Critchley H, Datta SR, McQuillin A, Blaveri E, Thirumalai S, et al. Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry 2006;63:844-54.
68. Munoz-Fernandez MA, Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol 1998;56:307-40.
69. De Simoni MG, Imeri L. Cytokine-neurotransmitter interactions in the brain. Biol Signals Recept 1998;7:33-44.
70. Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 1997;71:11-7.
71. Muller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1-33.
72. Hashimoto R, Yoshida M, Ozaki N, Yamanouchi Y, Iwata N, Suzuki T, et al. Association analysis of the -308G>A promoter polymorphism of the tumor necrosis factor alpha (TNF-alpha) gene in Japanese patients with schizophrenia. J Neural Transm 2004;111:217-21.
73. Schwab SG, Mondabon S, Knapp M, Albus M, Hallmayer J, Borrmann-Hassenbach M, et al. Association of tumor necrosis factor alpha gene -G308A polymorphism with schizophrenia. Schizophr Res 2003;65:19-25.
74. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996;2:788-94.
75. Wassink TH, Crowe RR, Andreasen NC. Tumor necrosis factor receptor-II: heritability and effect on brain morphology in schizophrenia. Mol Psychiatry 2000;5:678-82.
76. Barde YA. Neurotrophins: a family of proteins supporting the survival of neurons. Prog Clin Biol Res 1994;390:45-56.
77. Maisonpierre PC, Belluscio L, Friedman B, Alderson RF, Wiegand SJ, Furth ME, et al. NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 1990;5:501-9.
78. Hattori M, Kunugi H, Akahane A, Tanaka H, Ishida S, Hirose T, et al. Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am J Med Genet 2002;114:304-9.
79. Nanko S, Hattori M, Kuwata S, Sasaki T, Fukuda R, Dai XY, et al. Neurotrophin-3 gene polymorphism associated with schizophrenia. Acta Psychiatr Scand 1994;89:390-2.
80. Kunugi H, Hattori M, Nanko S, Fujii K, Kato T, Nanko S. Dinucleotide repeat polymorphism in the neurotrophin-3 gene and hippocampal volume in psychoses. Schizophr Res 1999;37:271-3.
81. Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, et al. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999;99:59-69.
82. Hartwig C, Veske A, Krejcova S, Rosenberger G, Finckh U. Plexin B3 promotes neurite outgrowth, interacts homophilically, and interacts with Rin. BMC Neurosci 2005;6:53.
83. Rujescu D, Meisenzahl EM, Krejcova S, Giegling I, Zetzsche T, Reiser M, et al. Plexin B3 is genetically associated with verbal performance and white matter volume in human brain. Mol Psychiatry 2007;12:190-4.
84. Trapp BD, Andrews SB, Cootauco C, Quarles R. The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes. J Cell Biol 1989;109:2417-26.
85. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003;362:798-805.
86. Hof PR, Haroutunian V, Copland C, Davis KL, Buxbaum JD. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem Res 2002;27:1193-200.
87. Bjartmar C, Yin X, Trapp BD. Axonal pathology in myelin disorders. J Neurocytol 1999;28:383-95.
88. Wan C, Yang Y, Feng G, Gu N, Liu H, Zhu S, et al. Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. Neurosci Lett 2005;388:126-31.
89. Yang YF, Qin W, Shugart YY, He G, Liu XM, Zhou J, et al. Possible association of the MAG locus with schizophrenia in a Chinese Han cohort of family trios. Schizophr Res 2005;75:11-9.
90. Felsky D, Voineskos AN, Lerch JP, Nazeri A, Shaikh SA, Rajji TK, et al. Myelin-associated glycoprotein gene and brain morphometry in schizophrenia. Front Psychiatry 2012;3:40.
91. Johnson MB, Kawasawa YI, Mason CE, Krsnik Z, Coppola G, Bogdanovic D, et al. Functional and evolutionary insights into human brain development through global transcriptome analysis. Neuron 2009;62:494-509.
92. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008;40:1053-5.
93. Biological insights from 108 schizophrenia-associated genetic loci. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Nature 2014;511:421-7.
94. Wassink TH, Epping EA, Rudd D, Axelsen M, Ziebell S, Fleming FW, et al. Influence of ZNF804a on brain structure volumes and symptom severity in individuals with schizophrenia. Arch Gen Psychiatry 2012;69:885-92.
95. Lencz T, Szeszko PR, DeRosse P, Burdick KE, Bromet EJ, Bilder RM, et al. A schizophrenia risk gene, ZNF804a, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology 2010;35:2284-91.
96. Kim DI, Manoach DS, Mathalon DH, Turner JA, Mannell M, Brown GG, et al. Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study. Hum Brain Mapp 2009;30:3795-811.
97. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signalling: cell fate control and signal integration in development. Science 1999;284:770-6.
98. Kopan R. Notch: a membrane-bound transcription factor. J Cell Sci 2002;115:1095-7.
99. Lowell S, Jones P, Le Roux I, Dunne J, Watt FM. Stimulation of human epidermal differentiation by delta-notch signalling at the boundaries of stem-cell clusters. Curr Biol 2000;10:491-500.
100. Uyttendaele H, Marazzi G, Wu G, Yan Q, Sassoon D, Kitajewski J. Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian notch gene. Development 1996;122:2251-9.
101. Wei J, Hemmings GP. The Notch4 locus is associated with susceptibility to schizophrenia. Nat Genet 2000;25:376-7.
102. Wassink TH, Nopoulos P, Pietila J, Crowe RR, Andreasen NC. Notch4 and the frontal lobe in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;118B:1-7.
103. Vernes SC, Spiteri E, Nicod J, Groszer M, Taylor JM, Davies KE, et al. High-throughput analysis of promoter occupancy reveals direct neural targets of FOXP2, a gene mutated in speech and language disorders. Am J Hum Genet 2007;81:1232-50.
104. Lai CS, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature 2001;413:519-23.
105. Li X, Branch CA, DeLisi LE. Language pathway abnormalities in schizophrenia: a review of fMRI and other imaging studies. Curr Opin Psychiatry 2009;22:131-9.
106. Sanjuan J, Tolosa A, Gonzalez JC, Aguilar EJ, Perez-Tur J, Najera C, et al. Association between FOXP2 polymorphisms and schizophrenia with auditory hallucinations. Psychiatr Genet 2006;16:67-72.
107. Spaniel F, Horacek J, Tintera J, Ibrahim I, Novak T, Cermak J, et al. Genetic variation in FOXP2 alters grey matter concentrations in schizophrenia patients. Neurosci Lett 2011;493:131-5.
108. Qiu Z, Sweeney DD, Netzeband JG, Gruol DL. Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons. J Neurosci 1998;18:10445-56.
109. Viviani B, Gardoni F, Marinovich M. Cytokines and neuronal ion channels in health and disease. Int Rev Neurobiol 2007;82:247-63.
110. Zakharyan R, Petrek M, Arakelyan A, Mrazek F, Atshemyan S, Boyajyan A. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 2012;80:136-42.
111. Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 2003;28:1515-20.
112. Baune BT, Konrad C, Grotegerd D, Suslow T, Birosova E, Ohrmann P, et al. Interleukin-6 gene (IL-6): a possible role in brain morphology in the healthy adult brain. J Neuroinflamm 2012;9:125.
113. Savitz J, Solms M, Ramesar R. Apolipoprotein E variants and cognition in healthy individuals: a critical opinion. Brain Res Rev 2006;51:125-35.
114. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55-61.
115. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996;19:1-17.
116. Harrington CR, Roth M, Xuereb JH, McKenna PJ, Wischik CM. Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. Neurosci Lett 1995;202:101-4.
117. Hata T, Kunugi H, Nanko S, Fukuda R, Kaminaga T. Possible effect of the APOE epsilon 4 allele on the hippocampal volume and asymmetry in schizophrenia. Am J Med Genet 2002;114:641-2.
118. Fernandez T, Yan WL, Hamburger S, Rapoport JL, Saunders AM, Schapiro M, et al. Apolipoprotein E alleles in childhoodonset schizophrenia. Am J Med Genet 1999;88:211-3.
119. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-34.
120. Dong Z, Zhou L, Del Villar K, Ghanevati M, Tashjian V, Miller CA. JIP1 regulates neuronal apoptosis in response to stress. Brain Res Mol Brain Res 2005;134:282-93.
121. Blanco S, Sanz-Garcia M, Santos CR, Lazo PA. Modulation of interleukin-1 transcriptional response by the interaction between VRK2 and the JIP1 scaffold protein. PLoS ONE 2008;3:e1660.
122. Dajas-Bailador F, Jones EV, Whitmarsh AJ. The JIP1 scaffold protein regulates axonal development in cortical neurons. Curr Biol 2008;18:221-6.
123. Steinberg S, de Jong S, Irish Schizophrenia Genomics Consortium. Andreassen OA, Werge T, Borglum AD, et al. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet 2011;20:4076-81.
124. Li M, Wang Y, Zheng XB, Ikeda M, Iwata N, Luo XJ, et al. MooDS Consortium. Meta-analysis and brain imaging data support the involvement of VRK2 (rs2312147) in schizophrenia susceptibility. Schizophr Res 2012;142:200-5.
125. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia - therapeutic implications. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl. 4):37-43.
126. Addington AM, Gornick M, Duckworth J, Sporn A, Gogtay N, Bobb A, et al. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry 2005;10:581-8.
127. Barnes A, Isohanni M, Barnett JH, Pietilainen O, Veijola J, Miettunen J, et al. Neuregulin-1 genotype is associated with structural differences in the normal human brain. Neuroimage 2012;59:2057-61.
128. Honea R, Verchinski BA, Pezawas L, Kolachana BS, Callicott JH, Mattay VS, et al. Impact of interacting functional variants in COMT on regional gray matter volume in human brain. Neuroimage 2009;45:44-51.
129. Lauder JM. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 1993;16:233-40.
130. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010;13:76-83.
131. Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998;12:21-36.
132. Meador-Woodruff JH, Clinton SM, Beneyto M, McCullumsmith RE. Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann N Y Acad Sci 2003;1003:75-93.
133. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008;9:437-52.
134. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002;71:877-92.
135. Hayashi Y. Long-term potentiation: two pathways meet at neurogranin. EMBO J 2009;28:2859-60.
136. Parlapani E, Schmitt A, Wirths O, Bauer M, Sommer C, Rueb U, et al. Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World J Biol Psychiatry 2010;11:243-50.
137. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006;60:132-40.
138. Hall J, Whalley HC, Job DE, Baig BJ, McIntosh AM, Evans KL, et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci 2006;9:1477-8.
139. McIntosh AM, Moorhead TW, Job D, Lymer GK, Munoz Maniega S, McKirdy J, et al. The effects of a neuregulin 1 variant on white matter density and integrity. Mol Psychiatry 2008;13:1054-9.
140. Sprooten E, Lymer GK, Munoz Maniega S, McKirdy J, Clayden JD, Bastin ME, et al. The relationship of anterior thalamic radiation integrity to psychosis risk associated neuregulin-1 variants. Mol Psychiatry 2009;14:237-8.
141. Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N, et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004;13:2699-708.
142. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem 2001;276:24232-41.
143. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002;71:337-48.
144. Funke B, Finn CT, Plocik AM, Lake S, DeRosse P, Kane JM, et al. Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet 2004;75:891-8.
145. Narr KL, Szeszko PR, Lencz T, Woods RP, Hamilton LS, Phillips O, et al. DTNBP1 is associated with imaging phenotypes in schizophrenia. Hum Brain Mapp 2009;30:3783-94.
146. Tognin S, Viding E, McCrory EJ, Taylor L, O'Donovan MC, McGuire P, et al. Effects of DTNBP1 genotype on brain development in children. J Child Psychol Psychiatry 2011;52:1287-94.
147. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003;361:417-9.
148. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002;99:13675-80.
149. Schumacher J, Jamra RA, Freudenberg J, Becker T, Ohlraun S, Otte AC, et al. Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry 2004;9:203-7.
150. Hartz SM, Ho BC, Andreasen NC, Librant A, Rudd D, Epping EA, et al. G72 influences longitudinal change in frontal lobe volume in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2010;153B:640-7.
151. Addington AM, Gornick M, Sporn AL, Gogtay N, Greenstein D, Lenane M, et al. Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. Biol Psychiatry 2004;55:976-80.
152. Detera-Wadleigh SD, McMahon FJ. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 2006;60:106-14.
153. Korostishevsky M, Kaganovich M, Cholostoy A, Ashkenazi M, Ratner Y, Dahary D, et al. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 2004;56:169-76.
154. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003;60:585-94.
155. Collingridge GL, Bliss TV. Memories of NMDA receptors and LTP. Trends Neurosci 1995;18:54-6.
156. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
157. Williams NM, Bowen T, Spurlock G, Norton N, Williams HJ, Hoogendoorn B, et al. Determination of the genomic structure and mutation screening in schizophrenic individuals for five subunits of the N-methyl-D-aspartate glutamate receptor. Mol Psychiatry 2002;7:508-14.
158. Itokawa M, Yamada K, Yoshitsugu K, Toyota T, Suga T, Ohba H, et al. A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 2003;13:271-8.
159. n polymorphism in the GRIN2A promoter with Japanese schizophrenia. Neurosci Lett 2005;378:102-5.
160. n polymorphisms in promoter region of N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene affect hippocampal and amygdala volumes. Genes Brain Behav 2010;9:269-75.
161. Schmid SM, Hollmann M. To gate or not to gate: are the delta subunits in the glutamate receptor family functional ion channels? Mol Neurobiol 2008;37:126-41.
162. Kuroyanagi T, Yokoyama M, Hirano T. Postsynaptic glutamate receptor delta family contributes to presynaptic terminal differentiation and establishment of synaptic transmission. Proc Natl Acad Sci U S A 2009;106:4912-6.
163. Treutlein J, Muhleisen TW, Frank J, Mattheisen M, Herms S, Ludwig KU, et al. Dissection of phenotype reveals possible association between schizophrenia and glutamate receptor Delta 1 (GRID1) gene promoter. Schizophr Res 2009;111:123-30.
164. Nenadic I, Maitra R, Scherpiet S, Gaser C, Schultz CC, Schachtzabel C, et al. Glutamate receptor Delta 1 (GRID1) genetic variation and brain structure in schizophrenia. J Psychiatr Res 2012;46:1531-9.
165. Rosso IM, Coyle JT, Ke Y, Gruber SA, Olson DP, Renshaw PF, et al. Cingulate cortex GABA concentration in schizophrenia: a two-dimensional proton magnetic resonance spectroscopy study. Biol Psychiatry 2006;59:1515.
166. Reynolds GP, Czudek C, Andrews HB. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatry 1990;27:1038-44.
167. Simpson MD, Slater P, Royston MC, Deakin JF. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res 1992;42:273-82.
168. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005;6:312-24.
169. Wassef A, Baker J, Kochan LD. GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol 2003;23:601-40.
170. Veldic M, Guidotti A, Maloku E, Davis JM, Costa E. In psychosis, cortical interneurons overexpress DNAmethyltransferase 1. Proc Natl Acad Sci U S A 2005;102:2152-7.
171. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000;57:237-45.
172. Brauns S, Gollub RL, Walton E, Hass J, Smolka MN, White T, et al. Genetic variation in GAD1 is associated with cortical thickness in the parahippocampal gyrus. J Psychiatr Res 2013;47:872-9.
173. Straub RE, Lipska BK, Egan MF, Goldberg TE, Callicott JH, Mayhew MB, et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry 2007;12:854-69.
174. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997;94:2569-74.
175. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996;93:9235-40.
176. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997;17:162-74.
177. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002;22:3708-19.
178. Backman L, Nyberg L, Soveri A, Johansson J, Andersson M, Dahlin E, et al. Effects of working-memory training on striatal dopamine release. Science 2011;333:718.
179. Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-Q11.2. Genomics 1992;12:822-5.
180. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807-21.
181. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008;13:570-84.
182. Ohnishi T, Hashimoto R, Mori T, Nemoto K, Moriguchi Y, Iida H, et al. The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain 2006;129:399-410.
183. Bailey LB, Gregory III JF. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999;129:919-22.
184. Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 2008;63:42-8.
185. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
186. Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 2005;26:361-71.
187. Kinoshita M, Numata S, Tajima A, Shimodera S, Imoto I, Ohmori T. Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia. Epigenetics 2013;8:584-90.
188. Joober R, Benkelfat C, Lal S, Bloom D, Labelle A, Lalonde P, et al. Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia. Mol Psychiatry 2000;5:323-6.
189. Kempisty B, Mostowska A, Gorska I, Luczak M, Czerski P, Szczepankiewicz A, et al. Association of 677C>T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene with bipolar disorder and schizophrenia. Neurosci Lett 2006;400:267-71.
190. Zhang Y, Yan H, Tian L, Wang F, Lu T, Wang L, et al. Association of MTHFR C677T polymorphism with schizophrenia and its effect on episodic memory and gray matter density in patients. Behav Brain Res 2013;243:146-52.
191. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76.
192. Aghajanian GK. Electrophysiological studies on the actions of hallucinogenic drugs at 5-HT2 receptors in rat brain. NIDA Res Monogr 1994;146:183-202.
193. Sodhi MS, Sanders-Bush E. Serotonin and brain development. Int Rev Neurobiol 2004;59:111-74.
194. Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B, et al. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry 2010;67:9-16.
195. Reynolds CA, Jansson M, Gatz M, Pedersen NL. Longitudinal change in memory performance associated with HTR2A polymorphism. Neurobiol Aging 2006;27:150-4.
196. Ni J, Lu W, Wu Z, Chen J, Yi Z, Zhang C. T102C polymorphism of serotonin 2A type receptor gene confers susceptibility to (early onset) schizophrenia in Han Chinese: an association study and meta-analysis. Asia Pac Psychiatry 2013;5:24-30.
197. Ozaki N, Manji H, Lubierman V, Lu SJ, Lappalainen J, Rosenthal NE, et al. A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 1997;68:2186-93.
198. de Quervain DJ, Henke K, Aerni A, Coluccia D, Wollmer MA, Hock C, et al. A functional genetic variation of the 5-HT2A receptor affects human memory. Nat Neurosci 2003;6:1141-2.
199. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 1993;50:810-8.
200. Filippini N, Scassellati C, Boccardi M, Pievani M, Testa C, Bocchio-Chiavetto L, et al. Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. Eur J Hum Genet 2006;14:443-9.
201. De Blasi A, Conn PJ, Pin J, Nicoletti F. Molecular determinants of metabotropic glutamate receptor signalling. Trends Pharmacol Sci 2001;22:114-20.
202. Ghavami A, Hunt RA, Olsen MA, Zhang J, Smith DL, Kalgaonkar S, et al. Differential effects of regulator of G protein signalling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signalling and adenylyl cyclase activity. Cell Signal 2004;16:711-21.
203. Beyer CE, Ghavami A, Lin Q, Sung A, Rhodes KJ, Dawson LA, et al. Regulators of G-protein signalling 4: modulation of 5-HT1A-mediated neurotransmitter release in vivo. Brain Res 2004;1022:214-20.
204. Hollinger S, Hepler JR. Cellular regulation of RGS proteins: modulators and integrators of G protein signalling. Pharmacol Rev 2002;54:527-59.
205. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004;27:107-44.
206. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signalling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 2001;6:293-301.
207. Williams NM, Preece A, Spurlock G, Norton N, Williams HJ, McCreadie RG, et al. Support for RGS4 as a susceptibility gene for schizophrenia. Biol Psychiatry 2004;55:192-5.
208. Mukai J, Dhilla A, Drew LJ, Stark KL, Cao L, MacDermott AB, et al. Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat Neurosci 2008;11:1302-10.
209. Drew LJ, Crabtree GW, Markx S, Stark KL, Chaverneff F, Xu B, et al. The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders. Int J Dev Neurosci 2011;29:259-81.
210. Hayashi T, Rumbaugh G, Huganir RL. Differential regulation of AMPA receptor subunit trafficking by palmitoylation of two distinct sites. Neuron 2005;47:709-23.
211. Faul T, Gawlik M, Bauer M, Jung S, Pfuhlmann B, Jabs B, et al. ZDHHC8 as a candidate gene for schizophrenia: analysis of a putative functional intronic marker in case-control and family-based association studies. BMC Psychiatry 2005;5:35.
212. Ota VK, Gadelha A, Assuncao IB, Santoro ML, Christofolini DM, Bellucco FT, et al. ZDHHC8 gene may play a role in cortical volumes of patients with schizophrenia. Schizophr Res 2013;145:33-5.
213. Li GL, Farooque M, Lewen A, Lennmyr F, Holtz A, Olsson Y. MAP2 and neurogranin as markers for dendritic lesions in CNS injury. An immunohistochemical study in the rat. APMIS 2000;108:98-106.
214. Pak JH, Huang FL, Li J, Balschun D, Reymann KG, Chiang C, et al. Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci U S A 2000;97:11232-7.
215. Husson M, Enderlin V, Alfos S, Feart C, Higueret P, Pallet V. Triiodothyronine administration reverses vitamin a deficiency-related hypo-expression of retinoic acid and triiodothyronine nuclear receptors and of neurogranin in rat brain. Br J Nutr 2003;90:191-8.
216. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 1994;6:348-57.
217. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature 2009;460:744-7.
218. Ohi K, Hashimoto R, Yasuda Y, Nemoto K, Ohnishi T, Fukumoto M, et al. Impact of the genome wide supported NRGN gene on anterior cingulate morphology in schizophrenia. PLoS ONE 2012;7:e29780.
219. Missler M, Fernandez-Chacon R, Sudhof TC. The making of neurexins. J Neurochem 1998;71:1339-47.
220. Reissner C, Klose M, Fairless R, Missler M. Mutational analysis of the neurexin/neuroligin complex reveals essential and regulatory components. Proc Natl Acad Sci U S A 2008;105:15124-9.
221. Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M, et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 2008;17:458-65.
222. Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, Toulopoulou T, et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 2009;18:988-96.
223. Voineskos AN, Lett TA, Lerch JP, Tiwari AK, Ameis SH, Rajji TK, et al. Neurexin-1 and frontal lobe white matter: an overlapping intermediate phenotype for schizophrenia and autism spectrum disorders. PLoS ONE 2011;6:e20982.
224. Lett TA, Tiwari AK, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, et al. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophr Res 2011;132:121-4.
225. Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol Psychiatry 2011;69:188-93.
226. Almasy L, Gur RC, Haack K, Cole SA, Calkins ME, Peralta JM, et al. A genome screen for quantitative trait loci influencing schizophrenia and neurocognitive phenotypes. Am J Psychiatry 2008;165:1185-92.
227. Lien YJ, Liu CM, Faraone SV, Tsuang MT, Hwu HG, Hsiao PC, et al. A genome-wide quantitative trait loci scan of neurocognitive performances in families with schizophrenia. Genes Brain Behav 2010;9:695-702.
228. Williams NM, O'Donovan MC, Owen MJ. Chromosome 22 deletion syndrome and schizophrenia. Int Rev Neurobiol 2006;73:1-27.
229. Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 1995;92:7612-6.
230. Bassett AS, Chow EW. 22q11 deletion syndrome: a genetic subtype of schizophrenia. Biol Psychiatry 1999;46:882-91.
231. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999;56:940-5.
232. Rare chromosomal deletions and duplications increase risk of schizophrenia. International Schizophrenia Consortium. Nature 2008;455:237-41.
233. Propping P, Nothen MM. Schizophrenia: genetic tools for unraveling the nature of a complex disorder. Proc Natl Acad Sci U S A 1995;92:7607-8.
234. Chow EW, Ho A, Wei C, Voormolen EH, Crawley AP, Bassett AS. Association of schizophrenia in 22q11.2 deletion syndrome and gray matter volumetric deficits in the superior temporal gyrus. Am J Psychiatry 2011;168:522-9.
235. John JP. Fronto-temporal dysfunction in schizophrenia: a selective review. Indian J Psychiatry 2009;51:180-90.
236. Chow EW, Zipursky RB, Mikulis DJ, Bassett AS. Structural brain abnormalities in patients with schizophrenia and 22q11 deletion syndrome. Biol Psychiatry 2002;51:208-15.
237. Schaer M, Debbane M, Bach Cuadra M, Ottet MC, Glaser B, Thiran JP, et al. Deviant Trajectories of cortical maturation in 22q11.2 deletion syndrome (22q11DS): a cross-sectional and longitudinal study. Schizophr Res 2009;115:182-90.
238. van Amelsvoort T, Daly E, Henry J, Robertson D, Ng V, Owen M, et al. Brain anatomy in adults with velocardiofacial syndrome with and without schizophrenia: preliminary results of a structural magnetic resonance imaging study. Arch Gen Psychiatry 2004;61:1085-9.
239. Liu J, Ulloa A, Perrone-Bizzozero N, Yeo R, Chen J, Calhoun VD. A pilot study on collective effects of 22q13.31 deletions on gray matter concentration in schizophrenia. PLoS ONE 2012;7:e52865.
240. Zinkstok J, Schmitz N, van Amelsvoort T, Moeton M, Baas F, Linszen D. Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia. Genes Brain Behav 2008;7:61-9.
241. Nawa H, Takahashi M, Patterson PH. Cytokine and growth factor involvement in schizophrenia - support for the developmental model. Mol Psychiatry 2000;5:594-603.
242. Katila H, Appelberg B, Hurme M, Rimon R. Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res 1994;12:29-34.
243. Rosa A, Peralta V, Papiol S, Cuesta MJ, Serrano F, Martinez-Larrea A, et al. Interleukin-1beta (IL-1beta) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2004;124B:10-4.
244. Hurme M, Santtila S. IL-1 receptor antagonist (Il-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998;28:2598-602.
245. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN∗2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 1998;47:195-8.
246. Papiol S, Molina V, Desco M, Rosa A, Reig S, Gispert JD, et al. Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. Neuroimage 2005;27:1002-6.
247. Kim SJ, Lee HJ, Koo HG, Kim JW, Song JY, Kim MK, et al. Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder. Psychiatr Genet 2004;14:165-7.
248. Xu M, He L. Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. Schizophr Res 2010;120:131-42.
249. Meisenzahl EM, Rujescu D, Kirner A, Giegling I, Kathmann N, Leinsinger G, et al. Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am J Psychiatry 2001;158:1316-9.
250. Schork NJ, Greenwood TA, Braff DL. Statistical genetics concepts and approaches in schizophrenia and related neuropsychiatric research. Schizophr Bull 2007;33:95-104.
251. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J. Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007;20:687-702.
252. Bennett CM, Wolford GL, Miller MB. The principled control of false positives in neuroimaging. Soc Cogn Affect Neurosci 2009;4:417-22.
253. Thirunavukkarasu P, Vijayakumari AA, John JP, Halahalli HN, Paul P, Sen S, et al. An exploratory association study of the influence of dysbindin and neuregulin polymorphisms on brain morphometry in patients with schizophrenia and healthy subjects from south India. Asian J Psychiatry 2014;10:62-8.
254. Burke L, Androutsos C, Jogia J, Byrne P, Frangou S. The Maudsley Early Onset Schizophrenia Study: the effect of age of onset and illness duration on fronto-parietal gray matter. Eur Psychiatry 2008;23:233-6.
255. Schwarzkopf SB, Olson SC, Coffman JA, Nasrallah HA. Third and lateral ventricular volumes in schizophrenia: support for progressive enlargement of both structures. Psychopharmacol Bull 1990;26:385-91.
256. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet 1994;344:1434.
257. Borne J, Riascos R, Cuellar H, Vargas D, Rojas R. Neuroimaging in drug and substance abuse part II: opioids and solvents. Top Magn Reson Imaging 2005;16:239-45.
258. Spampinato MV, Castillo M, Rojas R, Palacios E, Frascheri L, Descartes F. Magnetic resonance imaging findings in substance abuse: alcohol and alcoholism and syndromes associated with alcohol abuse. Top Magn Reson Imaging 2005;16:223-30.
259. Koutsouleris N, Gaser C, Jager M, Bottlender R, Frodl T, Holzinger S, et al. Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. Neuroimage 2008;39:1600-12.
260. Barnes J, Ridgway GR, Bartlett J, Henley SM, Lehmann M, Hobbs N, et al. Head size, age and gender adjustment in MRI studies: a necessary nuisance? Neuroimage 2010;53:1244-55.
261. Davidson LL, Heinrichs RW. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 2003;122:69-87.
262. Good CD, Johnsrude I, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. Cerebral asymmetry and the effects of sex and handedness on brain structure: a voxel-based morphometric analysis of 465 normal adult human brains. Neuroimage 2001;14:685-700.
263. Jovicich J, Czanner S, Han X, Salat D, van der Kouwe A, Quinn B, et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 2009;46:177-92.
264. Liu H, Abecasis GR, Heath SC, Knowles A, Demars S, Chen YJ, et al. Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc Natl Acad Sci U S A 2002;99:16859-64.
265. Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS, et al. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis 1994;182:476-8.
266. Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, et al. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet 2012;44:552-61.
267. Novak NM, Stein JL, Medland SE, Hibar DP, Thompson PM, Toga AW. EnigmaVis: online interactive visualization of genome-wide association studies of the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) Consortium. Twin Res Hum Genet 2012;15:414-8.
268. Hibar DP, van Erp TGM, Turner JA, Haukvik UK, Agartz I, et al. Meta-analysis of structural brain differences in bipolar disorder: the ENIGMA-bipolar disorder project. 19th annual meeting of the organization for human brain mapping. 2013.
269. den Braber A, Bohlken MM, Brouwer RM, van 't Ent D, Kanai R, Kahn RS, et al. Heritability of subcortical brain measures: a perspective for future genome-wide association studies. Neuroimage 2013;83:98-102.
270. Turner JA, Hibar DP, Rasmussen J, Andreassen O, Haukvik UK, Agartz I, et al. A prospective meta-analysis of subcortical brain volumes in schizophrenia via the ENIGMA consortium. Proc. organization of human brain mapping. 2013.
271. van Erp TGM, Hibar DP, Rasmussen J, Potkin S, Ophoff R, Andreassen O, et al. A large-scale meta-analysis of subcortical brain volume abnormalities in schizophrenia via the ENIGMA consortium. Society for Biological Psychiatry (SOBP). 2013.
272. Kochunov P, Jahanshad N, Sprooten E, Thompson P, McIntosh A, Deary I, et al. Genome-wide association of full brain white matter integrity - from the ENIGMA DTI working group. Organization of human brain mapping. 2012.
273. Thompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, et al. The Enigma Consortium: large-scale collaborative analyses of neuroimaging and genetic Data. Brain Imaging Behav 2014;8:153-82.
274. Hass J, Walton E, Kirsten H, Liu J, Priebe L, Wolf C, et al. A genome-wide association study suggests novel loci associated with a schizophrenia-related brain-based phenotype. PLoS ONE 2013;8:e64872.
275. Mechanic LE, Luke BT, Goodman JE, Chanock SJ, Harris CC. Polymorphism interaction analysis (PIA): a method for investigating complex gene-gene interactions. BMC Bioinform 2008;9:146.
276. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003;19:376-8.
277. Ritchie MD, Hahn LW, Moore JH. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003;24:150-7.
278. Wen X, Fuhrman S, Michaels GS, Carr DB, Smith S, Barker JL, et al. Large-scale temporal gene expression mapping of central nervous system development. Proc Natl Acad Sci U S A 1998;95:334-9.
279. Rhoades RW, Bennett-Clarke CA, Shi MY, Mooney RD. Effects of 5-HT on thalamocortical synaptic transmission in the developing Rat. J Neurophysiol 1994;72:2438-50.
280. Upton AL, Salichon N, Lebrand C, Ravary A, Blakely R, Seif I, et al. Excess of serotonin (5-HT) alters the segregation of ispilateral and contralateral retinal projections in monoamine oxidase a knock-out mice: possible role of 5-HT uptake in retinal ganglion cells during development. J Neurosci 1999;19:7007-24.
281. Hernandez DG, Nalls MA, Moore M, Chong S, Dillman A, Trabzuni D, et al. Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol Dis 2012;47:20-8.
282. Hovatta I, Zapala MA, Broide RS, Schadt EE, Libiger O, Schork NJ, et al. DNA variation and brain region-specific expression profiles exhibit different relationships between inbred mouse strains: implications for eQTL mapping studies. Genome Biol 2007;8:R25.
283. Brennand KJ, Gage FH. Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia. Stem Cells 2011;29:1915-22.
284. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The geneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 2010;38:214-20.
285. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 2013;154:518-29.